Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 187-195

  Mazhnaya, Alyona ^a,b   Meteliuk, Anna ^a   Barnard, Tetiana ^a   Zelenev, Alexei ^c   Filippovych, Sergii ^a   Altice, Frederick L ^c,d  

^a ALLIANCE FOR PUBLIC HEALTH   (Ukraine)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

DAA; HCV; PWID; Treatment scale up; Ukraine

Indexed keywords

BUPRENORPHINE; METHADONE; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DISEASE REGISTRY; DISEASE TRANSMISSION; FEASIBILITY STUDY; FEMALE; GENOTYPE; HEALTH CARE FACILITY; HEALTH SERVICE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SOCIAL SUPPORT; UKRAINE; COMPLICATION; GENETICS; HEPACIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK FACTOR; SEX FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; SUPPLY AND DISTRIBUTION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; COINFECTION; FEMALE; GENOTYPE; HEALTH SERVICES; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS; SEX FACTORS; SOFOSBUVIR; SUBSTANCE ABUSE, INTRAVENOUS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; UKRAINE; YOUNG ADULT;

EID: 85028350673     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.07.023     Document Type: Article

References (44)

1. Alliance for Public Health (2012). Analytical Report “Results of Sociological Research: Estimation of the size of high risk groups for HIV transmission in Ukraine in 2011”. Retrieved from Kyiv: http://www.aidsalliance.org.ua/ru/library/our/2013/SE_2012_Ukr.pdf.
2. Alliance for Public Health (2015). Monitoring of behavior and HIV prevalence in people who inject drugs and their sexual partners in Ukraine. http://aph.org.ua/wp-content/uploads/2015/09/Monitoryng-povedinky-SIN_PROEKT.pdf: Alliance for Public Health.
3. Alliance for Public Health (2016a). HCV treatment project in Ukraine. Scaling up accessible and effective HCV treatment through a community-based treatment model for most vulnerable populations in resource-constrained Ukraine. Retrieved from http://aph.org.ua/wp-content/uploads/2016/07/HCVtreatment.pdf.
4. Alliance for Public Health (2016b). Scaling up accessible and effective HCV treatment through a community-based treatment model for most vulnerable populations in resource-constrained Ukraine. Projects. Retrieved from http://aph.org.ua/en/our-works/ukraine/scaling-up-accessible-and-effective-hcv-treatment-through-community-based-treatment-model-for-most-vulnerable-populations-in-the-resource-constrained-ukraine/.
5. Andrejczyn, M., Wasyliewa, N., Gospodarski, I., Some aspects of epidemiology of HCV infections in Ukraine. Przeglad Epidemiologiczny 59:2 (2005), 499–501.
6. Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D.H., Razavi, H., Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology & Hepatology 2:3 (2017), 161–176, 10.1016/s2468-1253(16)30181-9.
7. Boglione, L., Mornese Pinna, S., De Nicolo, A., Cusato, J., Cariti, G., Di Perri, G., et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. Journal of Viral Hepatitis 24:8 (2017), 1–8, 10.1111/jvh.1271 Epub date: 2017/03/28.
8. Bruggmann, P., Grebely, J., Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 26:Suppl. 1 (2015), S22–S26, 10.1016/j.drugpo.2014.08.014.
9. Bruggmann, P., Litwin, A.H., Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all. Clinical Infectious Diseases 57:Suppl. 2 (2013), S56–S61, 10.1093/cid/cit271.
10. Čakalo, J.-I., Božičević, I., Vitek, C., Mandel, J.S., Salyuk, T., Rutherford, G.W., Misclassification of men with reported HIV infection in Ukraine. AIDS and Behavior 19:10 (2015), 1938–1940.
11. Damschroder, L.J., Aron, D.C., Keith, R.E., Kirsh, S.R., Alexander, J.A., Lowery, J.C., Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implementation Science, 4, 2009, 50.
12. Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L.T., Hickman, M., Vos, T., Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: Findings from the Global Burden of Disease Study 2013. Lancet Infectious Diseases 16:12 (2016), 1385–1398, 10.1016/s1473-3099(16)30325-5.
13. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., C-EDGE CO-STAR Study Group, Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine 165:9 (2016), 625–634, 10.7326/M16-0816.
14. Dumchev, K.V., Soldyshev, R., Qian, H.Z., Zezyulin, O.O., Chandler, S.D., Slobodyanyuk, P., Schumacher, J.E., HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: A cross-sectional survey. Harm Reduction Journal, 6, 2009, 23, 10.1186/1477-7517-6-23.
15. Dutta, A., Wirtz, A.L., Baral, S., Beyrer, C., Cleghorn, F.R., Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Current Opinion in HIV and AIDS 7:4 (2012), 362–368, 10.1097/COH.0b013e328354a0b5.
16. Dutta, A., Perales, N., Semeryk, O., Balakireva, O., Т. Aleksandrina, Ieshchenko, O., Zelenska, M., Lives on the Line: Funding Needs and Impacts of Ukraine's National HIV/AIDS Program, 2014–2018. 2013, Futures Group, Health Policy Project, Washington, DC.
17. Grebely, J., Matthews, G.V., Lloyd, A.R., Dore, G.J., Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements. Clinical Infectious Diseases 57:7 (2013), 1014–1020, 10.1093/cid/cit377.
18. Grebely, J., Bruggmann, P., Treloar, C., Byrne, J., Rhodes, T., Dore, G.J., Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 26:10 (2015), 893–898, 10.1016/j.drugpo.2015.07.007.
19. Grebely, J., Dore, G.J., Zeuzem, S., Aspinall, R.J., Fox, R., Han, L., Feld, J.J., Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials. Clinical Infectious Diseases 63:11 (2016), 1479–1481, 10.1093/cid/ciw579.
20. Grebely, J., Mauss, S., Brown, A., Bronowicki, J.-P., Puoti, M., Wyles, D., Dore, G.J., Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials. Clinical Infectious Diseases 63:11 (2016), 1405–1411, 10.1093/cid/ciw580.
21. Gural, L., Mariievskii, V., Siergieieva, T., Shaginian, V., Kolos, L., Hepatitis C in Ukraine: Epidemiological aspects of the issue. Modern Infections, 2008, 53–63.
22. Gvinjilia, L., Nasrullah, M., Sergeenko, D., Tsertsvadze, T., Kamkamidze, G., Butsashvili, M., Averhoff, F., National progress toward hepatitis C elimination—Georgia, 2015–2016. Morbidity and Mortality Weekly Report (MMWR) 65:41 (2016), 1132–1135, 10.15585/mmwr.mm6541a2.
23. Harris, M., Albers, E., Swan, T., The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?. International Journal of Drug Policy 26:10 (2015), 963–969.
24. Hosmer, D.W., Lemeshow, S., Klar, J., Goodness-of-fit testing for the logistic regression model when the estimated probabilities are small. Biometrical Journal 30:8 (1988), 911–924, 10.1002/bimj.4710300805.
25. Kirk, G.D., Mehta, S.H., Astemborski, J., Galai, N., Washington, J., Higgins, Y., Thomas, D.L., HIV, age, and the severity of hepatitis C virus-related liver disease: A cohort study. Annals of Internal Medicine 158:9 (2013), 658–666, 10.7326/0003-4819-158-9-201305070-00604.
26. Luhmann, N., Champagnat, J., Golovin, S., Maistat, L., Agustian, E., Inaridze, I., Bouscaillou, J., Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia. International Journal of Drug Policy 26:11 (2015), 1081–1087.
27. Malta, M., Magnanini, M.M., Strathdee, S.A., Bastos, F.I., Adherence to antiretroviral therapy among HIV-infected drug users: A meta-analysis. AIDS and Behavior 14:4 (2010), 731–747, 10.1007/s10461-008-9489-7.
28. Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., Hickman, M., Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58:5 (2013), 1598–1609, 10.1002/hep.26431.
29. Mason, K., Dodd, Z., Guyton, M., Tookey, P., Lettner, B., Matelski, J., Powis, J., Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. International Journal of Drug Policy(June (12)), 2017, 1–7, 10.1016/j.drugpo.2017.05.025 pii: S0955-3959(17)30129-9 [Epub ahead of print].
30. Meyer, J.P., Moghimi, Y., Marcus, R., Lim, J.K., Litwin, A.H., Altice, F.L., Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. International Journal of Drug Policy 26:10 (2015), 922–935, 10.1016/j.drugpo.2015.05.002.
31. Milne, R., Price, M., Wallace, B., Drost, A., Haigh-Gidora, I., Nezil, F.A., et al. From principles to practice: Description of a novel equity-based HCV primary care treatment model for PWID. International Journal of Drug Policy 26:10 (2015), 1020–1027.
32. Ministry of Health of Ukraine (2014). Immune prevention of hepatitis is the most efficient way to fight against the disease. Retrieved from http://moz.gov.ua/ua/portal/pre_20140728_d.html.
33. Ministry of Health of Ukraine (2016). On approval and implementation of documentation on stardatization of medical help for Hepatitis C Virus.
34. Peters, D.H., Tran, N.T., Adam, T., Implementation research in health: A practical guide. 2014, World Health Organization.
35. Read, P., Lothian, R., Chronister, K., Gilliver, R., Kearley, J., Dore, G.J., et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. International Journal of Drug Policy(June (4)), 2017, 1–7, 10.1016/j.drugpo.2017.05.032 pii: S0955-3959(17)30136-6 [Epub ahead of print].
36. Smith, D.J., Combellick, J., Jordan, A.E., Hagan, H., Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. International Journal of Drug Policy 26:10 (2015), 911–921.
37. Stanaway, J.D., Flaxman, A.D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Cooke, G.S., The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. The Lancet 388:10049 (2016), 1081–1088, 10.1016/S0140-6736(16)30579-7.
38. Stata, Release 14. Statistical Software. College Station. StataCorp 2015. 2014, StataCorp LP, TX.
39. Stetler, C.B., Damschroder, L.J., Helfrich, C.D., Hagedorn, H.J., A guide for applying a revised version of the PARIHS framework for implementation. Implementation Science, 6, 2011, 99, 10.1186/1748-5908-6-99.
40. Sylla, L., Bruce, R.D., Kamarulzaman, A., Altice, F.L., Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. International Journal of Drug Policy 18:4 (2007), 306–312, 10.1016/j.drugpo.2007.03.001.
41. UNODC (2016). Word Drug Report 2016 (United Nations Publication, Sales No. E.16.XI.7). Vienna, Austria.
42. Vitek, C.R., Cakalo, J.I., Kruglov, Y.V., Dumchev, K.V., Salyuk, T.O., Bozicevic, I., Rutherford, G.W., Slowing of the HIV epidemic in Ukraine: Evidence from case reporting and key population surveys, 2005–2012. PLoS One, 9(9), 2014, e103657, 10.1371/journal.pone.0103657.
43. Wolfe, D., Luhmann, N., Harris, M., Momenghalibaf, A., Albers, E., Byrne, J., et al. Human rights and access to hepatitis C treatment for people who inject drugs. International Journal of Drug Policy 26:11 (2015), 1072–1080, 10.1016/j.drugpo.2015.05.007.
44. World Populatin Review (Producer) (2016, January 6th, 2017). Ukraine Population. WPR. Retrieved from http://worldpopulationreview.com/countries/ukraine-population/.